Glucagon-Like Peptide-2 (GLP-2)

Often transient and resolves within days to weeks of continued use. May be related to increased intestinal motility. Can be managed with consistent injection timing and ensuring adequate hydration.

Typically mild and self-resolving. May occur shortly after injection. Taking the injection at a consistent time and with food may help reduce incidence.

Erythema, swelling, or mild discomfort at injection site. Minimize by rotating injection sites, allowing solution to reach room temperature, and using proper injection technique. Usually resolves within hours.

Reported in some clinical trial participants. Typically mild and transient. Ensure adequate hydration and monitor frequency.

May occur due to improved intestinal function and nutrient absorption. Not necessarily adverse in short bowel syndrome patients who require increased caloric intake.

Reported rarely in clinical trials. Monitor for signs of peripheral edema, particularly in lower extremities. Ensure adequate electrolyte balance.

Rarely reported in clinical studies. Monitor mood and anxiety levels, particularly in individuals with pre-existing anxiety disorders.

GLP-2 may affect gallbladder contractility. Individuals with pre-existing gallbladder disease should use with caution and monitor for abdominal pain, nausea, or changes in bowel habits. Seek medical evaluation if symptoms develop.

Extremely rare but serious. Seek immediate medical attention if experiencing severe abdominal pain, elevated amylase/lipase levels, or other signs of pancreatitis. Discontinue use and consult healthcare provider.